Key result
Antiarrhythmic agents like digoxin frequently resolve fetal atrial flutter to prevent severe complications.
Early recognition and treatment of fetal atrial flutter with antiarrhythmic agents like digoxin is essential to prevent severe complications such as fetal hydrops, congestive heart failure, and fetal demise.
May prompt enhanced fetal surveillance for tachyarrhythmias; leaves open standardized management protocols pending higher-level evidence.
Fetal tachyarrhythmias are infrequently encountered in utero. They are divided into subgroups including: atrial flutter/fibrillation, supraventricular tachycardia (SVT), sinus tachycardia, and atrial extrasystoles. Tachyarrhythmias can lead to fetal hydrops, congestive heart failure, and possibly fetal demise. Atrial flutter in a fetus is defined by an atrial rate of 300 to 600 beats per minute (bpm), with or without a 1:1 conduction rate to the ventricles. Atrioventricular reentrant tachycardia (AVRT) is the most common cause of supraventricular tachycardia and should be considered in cases of atrial tachycardia. Recognition of cardiac dysrhythmias is essential in early intervention. Cardiac antiarrthymic agents are frequently used with success to convert fetal dysrhythmias to a normal sinus rhythm. Digoxin is typically first-line therapy, and in more advanced or severe cases, additional drugs are often used.
No takes yet. Share an insight, caveat, or question.
Sarah Martinez (2008) conducted a review in Fetal tachyarrhythmias and atrial flutter. Cardiac antiarrhythmic agents (e.g., Digoxin) was evaluated. Fetal atrial flutter can lead to severe complications like hydrops and heart failure, but is frequently treated successfully with antiarrhythmic agents such as digoxin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: